Translating FDA for Investors: Seattle Genetics Shrugs Off Public Lambasting at ODAC
This article was originally published in RPM Report
Executive Summary
Actions speak louder than words. That, at least, is how Seattle Genetics urged investors to think about a tongue lashing the company received during an advisory committee review of the cancer agent Adcetris Seattle Genetics may be right on two levels: the practical outcome of the meeting was positive, and the FDA rhetoric may not have been as directly aimed at the sponsor as a warning to all oncology drug developers.